clinic

Michael Ashburner (1942-) is Professor of Biology at the University of Cambridge and is the former Joint-Head of the European Bioinformatics Institute (EBI).He was educated at the Royal Grammar School, High Wycombe and the University of Cambridge, where he received his undergraduate degree (1964) and Ph.D. (1968), both in genetics. He then went to the California Institute of Technology as a postdoctoral fellow with Hershell Mitchell. In 1979, he returned to the Department of Genetics in...

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As...

Daniele Piomelli, PhD. - Another approach was discussed by D. Piomelli (University of California, Irvine). URB 597, an inhibitor of fatty acid amide hydrolase (FAAH), is expected to increase anandamide signaling and is being currently clinically tested in the therapy of pain. An increase in anandamide signaling may also be useful in the therapy of depression. This is a novel approach to the development of antidepressants. The signaling can be enhanced by blocking anadamide metabolism or by...